PE20060317A1 - Derivados de xantina como agonistas selectivos del receptor de acido nicotinico - Google Patents

Derivados de xantina como agonistas selectivos del receptor de acido nicotinico

Info

Publication number
PE20060317A1
PE20060317A1 PE2005000170A PE2005000170A PE20060317A1 PE 20060317 A1 PE20060317 A1 PE 20060317A1 PE 2005000170 A PE2005000170 A PE 2005000170A PE 2005000170 A PE2005000170 A PE 2005000170A PE 20060317 A1 PE20060317 A1 PE 20060317A1
Authority
PE
Peru
Prior art keywords
nicotinic acid
acid receptor
selective agonists
alkyl
diona
Prior art date
Application number
PE2005000170A
Other languages
English (en)
Inventor
Ivan Leo Pinto
Shahzad Sharooq Rahman
Neville Hubert Nicholson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0403282A external-priority patent/GB0403282D0/en
Priority claimed from GB0423562A external-priority patent/GB0423562D0/en
Priority claimed from GB0428375A external-priority patent/GB0428375D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20060317A1 publication Critical patent/PE20060317A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 H, ALQUILO C1-C4 SUSTITUIDO O NO POR CN, CF3; R2 ES ALQUILO C3-C10, ALQUILO C1-C10 SUSTITUIDO CON 1 O MAS GRUPOS DE F, CN, ENTRE OTROS; R3 ES HALOGENO, CN. SON COMPUESTOS PREFERIDOS: 8-CLORO-3-(4-PENTEN-1-IL)-3,7-DIHIDRO-1H-PURINA-2,6-DIONA; (8-CLORO-2,6-DIOXO-1,2,6,7-TETRAHIDRO-3H-PRIN-3-IL)ACETONITRILO; 8-CLORO-3-(4,4,4-TRIFLUOROBUTIL)-3,7-DIHIDRO-1H-PURINA-2,6-DIONA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON AGONISTAS SELECTIVOS DEL RECEPTOR DE ACIDO NICOTINICO HM74A UTILES EN ENFERMEDADES DEL METABOLISMO DE LIPIDOS, INSUFICIENCIA CARDIACA, ARTERIOSCLEROSIS, TROMBOSIS, ANGINA, ENTRE OTROS
PE2005000170A 2004-02-14 2005-02-11 Derivados de xantina como agonistas selectivos del receptor de acido nicotinico PE20060317A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403282A GB0403282D0 (en) 2004-02-14 2004-02-14 Chemical compounds
GB0423562A GB0423562D0 (en) 2004-10-22 2004-10-22 Novel compounds
GB0428375A GB0428375D0 (en) 2004-12-24 2004-12-24 Novel compounds

Publications (1)

Publication Number Publication Date
PE20060317A1 true PE20060317A1 (es) 2006-06-22

Family

ID=34864831

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000170A PE20060317A1 (es) 2004-02-14 2005-02-11 Derivados de xantina como agonistas selectivos del receptor de acido nicotinico

Country Status (26)

Country Link
US (5) US7713982B2 (es)
EP (1) EP1781657B1 (es)
JP (2) JP5001012B2 (es)
KR (1) KR101100601B1 (es)
CN (2) CN101103030B (es)
AR (1) AR047669A1 (es)
AU (1) AU2005212816C1 (es)
BR (1) BRPI0507604A (es)
CA (1) CA2556073C (es)
CY (1) CY1114022T1 (es)
DK (1) DK1781657T3 (es)
ES (1) ES2406732T3 (es)
HK (1) HK1104530A1 (es)
HR (1) HRP20130406T1 (es)
IL (1) IL177051A (es)
MA (1) MA28357A1 (es)
MY (1) MY148937A (es)
NO (1) NO337281B1 (es)
NZ (1) NZ548496A (es)
PE (1) PE20060317A1 (es)
PL (1) PL1781657T3 (es)
PT (1) PT1781657E (es)
SG (1) SG157242A1 (es)
SI (1) SI1781657T1 (es)
TW (1) TWI350289B (es)
WO (1) WO2005077950A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101255162A (zh) * 1999-11-12 2008-09-03 拜奥根Idec马萨诸塞公司 作为腺苷受体拮抗剂的多环烷基嘌呤
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
PE20050483A1 (es) 2003-10-31 2005-08-25 Arena Pharm Inc Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
KR101100601B1 (ko) * 2004-02-14 2011-12-29 글락소스미스클라인 엘엘씨 신규 화합물
AU2005311930B9 (en) 2004-12-03 2009-09-10 Merck Sharp & Dohme Corp. Substituted piperazines as CB1 antagonists
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US7750015B2 (en) 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
BRPI0610133A2 (pt) 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006259137B2 (en) * 2005-06-14 2010-04-01 F. Hoffmann-La Roche Ag Anthranilic acid derivatives
PL1901731T3 (pl) 2005-06-28 2011-08-31 Merck Sharp & Dohme Agoniści receptora niacyny, kompozycje zawierające te związki i sposoby leczenia
JP2009504592A (ja) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
KR20080091814A (ko) 2006-01-20 2008-10-14 쉐링 코포레이션 지질혈증장애의 치료를 위한 니코틴산 수용체 효능제로서의헤테로사이클
WO2007134986A1 (en) * 2006-05-23 2007-11-29 F. Hoffmann-La Roche Ag Pyridopyrimidinone derivatives
TW200804383A (en) * 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
DE602007010312D1 (de) * 2006-06-23 2010-12-16 Incyte Corp Purinonderivate als hm74a-agonisten
EP2044074A2 (en) 2006-06-23 2009-04-08 Incyte Corporation Purinone derivatives as hm74a agonists
JP2010521513A (ja) 2007-03-23 2010-06-24 エフ．ホフマン−ラ ロシュ アーゲー アザ−ピリドピリミジノン誘導体
AU2009324811B2 (en) * 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
CN102276610B (zh) * 2011-05-04 2013-01-09 北京工业大学 N7-鸟嘌呤烷化物的制备方法
CN103360394B (zh) * 2013-07-29 2015-07-22 上海万巷制药有限公司 8-氯茶碱的制备方法
SG10201907026RA (en) * 2015-01-30 2019-09-27 Shanton Pharma Co Ltd Prevention or Treatment of Uratic or Gouty Diseases
CN104892610B (zh) * 2015-05-27 2016-08-24 福建师范大学 一种8-酯基咖啡因衍生物的制备方法
CN105622610A (zh) * 2016-03-28 2016-06-01 浙江诚意药业股份有限公司 一种黄嘌呤化合物的制备方法
WO2018019911A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sarl Therapeutic combinations to treat red blood cell disorders
CN106632061B (zh) * 2016-11-23 2020-07-24 上海皓元医药股份有限公司 一种1-(4-苯基-1-烷基-1h-咪唑-2-基)乙酮及其衍生物的合成方法
AU2018208422B2 (en) 2017-01-10 2021-11-11 Bayer Aktiengesellschaft Heterocyclene derivatives as pest control agents
JP2022549807A (ja) * 2019-09-25 2022-11-29 ゴールドフィンチ バイオ，インク． キサンチンｃｂ１阻害物質
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CN113262882B (zh) * 2021-07-21 2021-09-17 北京矿冶研究总院 阳离子捕收剂、制备方法及在磷矿反浮选中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) * 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
US4847377A (en) * 1985-05-13 1989-07-11 Schering Corporation Substituted-2,3-dihydro-6-substituted-pyrimido[2,1-F]-purine-4,8(1H,9H)-diones
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) * 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
WO1993016699A1 (en) * 1992-02-21 1993-09-02 Smithkline Beecham Corporation Tnf inhibitors
WO1993017684A2 (en) 1992-03-04 1993-09-16 Cell Therapeutics, Inc. Enantiomeric hydroxylated xanthine compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
WO1995020589A1 (en) 1994-01-28 1995-08-03 Cell Therapeutics, Inc. Cell signaling inhibitors
US6103730A (en) 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
CA2183562A1 (en) 1994-02-18 1995-08-24 J. Peter Klein Intracellular signalling mediators
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US5801182A (en) 1994-03-24 1998-09-01 Cell Therapeutics, Inc. Amine substituted compounds
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
EP1171442B1 (en) 1999-04-09 2005-12-07 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signalling inhibitors
US20030207901A1 (en) 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
WO2001016134A1 (en) * 1999-08-31 2001-03-08 Vanderbilt University Selective antagonists of a2b adenosine receptors
EP1305328A2 (en) * 2000-07-21 2003-05-02 Mark B. Lyles Materials and methods for binding nucleic acids to surfaces
FR2812482B1 (fr) * 2000-07-28 2003-01-24 Inside Technologies Dispositif electronique portable comprenant plusieurs circuits integres sans contact
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
AU2002210521A1 (en) * 2000-09-19 2002-04-02 Novimmune S.A. Use of statins (HMG-CoA reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
PT1368349E (pt) 2001-02-24 2007-04-30 Boehringer Ingelheim Pharma Derivados de xantina, sua preparação e sua utilização como medicamento
AU2002242910A1 (en) * 2001-04-11 2002-10-28 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
KR101100601B1 (ko) * 2004-02-14 2011-12-29 글락소스미스클라인 엘엘씨 신규 화합물
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
JP2009504592A (ja) * 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
EP1939197A1 (en) * 2006-12-22 2008-07-02 Schwarz Pharma Ag 8-ethinylxanthine derivatives as selective A2A receptor antagonists
AU2009324811B2 (en) * 2008-12-08 2013-01-24 Glaxosmithkline Llc Novel compounds
US20110065676A1 (en) * 2009-06-24 2011-03-17 Schering Corporation Combination therapies comprising par1 antagonists with nar agonists

Also Published As

Publication number Publication date
SG157242A1 (en) 2009-12-29
WO2005077950A2 (en) 2005-08-25
US20100010021A1 (en) 2010-01-14
TW200536537A (en) 2005-11-16
US7713982B2 (en) 2010-05-11
CN101863888B (zh) 2012-07-18
DK1781657T3 (da) 2013-06-10
CA2556073C (en) 2012-01-10
ES2406732T3 (es) 2013-06-07
IL177051A (en) 2013-01-31
JP2008120831A (ja) 2008-05-29
AU2005212816B2 (en) 2009-07-23
AU2005212816A1 (en) 2005-08-25
AR047669A1 (es) 2006-02-01
BRPI0507604A (pt) 2007-07-03
NO337281B1 (no) 2016-02-29
US20150080418A1 (en) 2015-03-19
MY148937A (en) 2013-06-14
TWI350289B (en) 2011-10-11
JP5001012B2 (ja) 2012-08-15
PL1781657T3 (pl) 2013-08-30
NO20064151L (no) 2006-11-06
US20100160354A1 (en) 2010-06-24
CA2556073A1 (en) 2005-08-25
AU2005212816C1 (en) 2010-03-04
CN101103030B (zh) 2010-10-13
JP5020848B2 (ja) 2012-09-05
US8394808B2 (en) 2013-03-12
IL177051A0 (en) 2006-12-10
KR101100601B1 (ko) 2011-12-29
WO2005077950A3 (en) 2007-04-19
US8268839B2 (en) 2012-09-18
HRP20130406T1 (hr) 2013-06-30
SI1781657T1 (sl) 2013-07-31
MA28357A1 (fr) 2006-12-01
KR20060126772A (ko) 2006-12-08
CN101103030A (zh) 2008-01-09
US20130150383A1 (en) 2013-06-13
JP2007522176A (ja) 2007-08-09
CY1114022T1 (el) 2016-07-27
HK1104530A1 (en) 2008-01-18
US20070135456A1 (en) 2007-06-14
CN101863888A (zh) 2010-10-20
EP1781657B1 (en) 2013-03-27
PT1781657E (pt) 2013-05-23
NZ548496A (en) 2010-02-26
EP1781657A2 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
PE20060317A1 (es) Derivados de xantina como agonistas selectivos del receptor de acido nicotinico
PE20060949A1 (es) Derivados fusionados de pirazol como agonistas del receptor de niacina
PE20061442A1 (es) Heterociclicos como agonistas del receptor de acido nicotinico para el tratamiento de dislipidemia
AR038419A1 (es) Derivados de piridina y quinolina
PE20140630A1 (es) Derivados de acido 3-fenilpropionico ramificados y su uso
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
PE20130402A1 (es) 5-fluoro-1h-pirazolopiridinas sustituidas y su uso
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20080421A1 (es) Derivados de 5,6-bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii
PE20030940A1 (es) Derivados de piridina y pirimidina
CY1114092T1 (el) Σπειρο υποκατεστημενες ενωσεις ως αναστολεις αγγειογενεσης
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
AR072557A1 (es) Proceso para preparar composiciones de medicamentos que contienen dabigatran
PE20070706A1 (es) Nuevos derivados imidazopiridina como antagonistas de adenosina a2b
PE20140250A1 (es) Derivados de piperidina puenteada
Glennon et al. The medicinal chemistry of 5-HT6 receptor ligands with a focus on arylsulfonyltryptamine analogs
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
UY27965A1 (es) Derivados heterocíclicos
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
AR060914A1 (es) Derivados de furopiridina como ligandos receptores de la acetilcolina nicotinica, una composicion farmaceutica que los comprende y su empleo en la manufactura de un medicamento para el tratamiento de una enfermedad mediada por la activacion del receptor alfa7-nicotinico.
ATE427926T1 (de) Cycloalkylaminderivate
CY1106375T1 (el) Χρηση της επιγαστινης για την αντιμετωπιση αλλepγικης ρινιτιδας/επιπεφυκιτιδας
EA200802203A1 (ru) Дикетопиперазиновые и пиперидиновые производные в качестве противовирусных агентов
AR052314A1 (es) Compuestos de tienopiridinona como agonistas del receptor 5-ht4
AR023971A1 (es) Derivados de 4,5,6,7-tetrahidroindazol, procedimiento para la preparacion de los mismos y su utilizacion como agentes antitumorales

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed